Secondary Logo

Journal Logo

Prostate Cancer: Markers (MP60): Moderated Poster 60: Monday, September 13, 2021

MP60-19 CELL-FREE DNA AND ANDROGEN RECEPTOR AMPLIFICATION CORRELATE WITH CLINICAL OUTCOMES IN CASTRATION-RESISTANT PROSTATE CANCER

Kubota, Yuka; Hatakeyama, Shingo; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Ohyama, Chikara

doi: 10.1097/JU.0000000000002095.19
  • Free

INTRODUCTION AND OBJECTIVE:

To investigate the prognostic significance of total cell-free DNA (cfDNA) and androgen receptor amplification (AR -amp) in patients with castration-resistant prostate cancer (CRPC).

METHODS:

We retrospectively compared the total cfDNA and AR -amp levels in 42 individuals without prostate cancer, 57 patients with localized prostate cancer without androgen deprivation therapy (ADT), 97 patients with castration-sensitive prostate cancer (CSPC) with ADT, and 97 patients with CRPC. The association of these cfDNA biomarkers on disease status and overall survival was evaluated using Kaplan–Meier analysis and multivariable Cox regression analysis. Finally, a simple risk model was developed including total cfDNA and AR -amp to predict poor prognosis.

RESULTS:

The median total cfDNA and AR -amp levels in patients with CRPC was 387 pg/μL and 1.07 copies, respectively. The total cfDNA and AR -amp levels were significantly higher in the patients with CRPC than in individuals without prostate cancer, patients with localized prostate cancer without ADT, and patients with CSPC with ADT. Total cfDNA-high (>600 pg/μL) and AR -amp-high (>1.26 copies) were significantly associated with poor overall survival. Multivariable Cox regression analysis showed cfDNA-high and AR -amp -high were significantly associated with poor overall survival in patients with CRPC. We developed a risk model using cfDNA-high (score 1) and AR -amp-high (score 1). The risk score 1-2 was significantly associated with worse overall survival than score 0.

CONCLUSIONS:

Total cfDNA and AR -amp levels are potential biomarkers for poor prognosis in patients with CRPC.

Source of Funding:

The authors have no conflicts of interest associated with this manuscript.

© 2021 by American Urological Association Education and Research, Inc.